Uniqure NV (NASDAQ:QURE) shares were down 7.3% during mid-day trading on Friday . The stock traded as low as $63.22 and last traded at $63.43. Approximately 589,379 shares traded hands during mid-day trading, an increase of 10% from the average daily volume of 536,403 shares. The stock had previously closed at $68.41.
Several research analysts have issued reports on QURE shares. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective (up previously from $48.00) on shares of Uniqure in a research report on Monday, November 26th. Chardan Capital reiterated a “buy” rating and issued a $70.00 price objective on shares of Uniqure in a research report on Monday, December 3rd. Guggenheim started coverage on Uniqure in a research report on Monday, December 17th. They issued a “buy” rating and a $35.00 price objective for the company. B. Riley started coverage on Uniqure in a research report on Monday, December 31st. They issued a “buy” rating and a $72.00 price objective for the company. Finally, Zacks Investment Research cut Uniqure from a “hold” rating to a “sell” rating in a research report on Friday, January 11th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $73.00.
The company has a quick ratio of 11.85, a current ratio of 11.85 and a debt-to-equity ratio of 0.20. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of -27.11 and a beta of 1.07.
In other Uniqure news, CAO Christian Klemt sold 1,479 shares of the company’s stock in a transaction on Monday, January 28th. The stock was sold at an average price of $31.29, for a total value of $46,277.91. Following the sale, the chief accounting officer now owns 56,085 shares of the company’s stock, valued at $1,754,899.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 67,376 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $63.96, for a total value of $4,309,368.96. The disclosure for this sale can be found here. Insiders sold 113,390 shares of company stock worth $5,764,148 in the last three months. 1.56% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of QURE. Northern Trust Corp bought a new position in Uniqure during the 2nd quarter worth about $602,000. Wells Fargo & Company MN grew its holdings in Uniqure by 24.2% during the 3rd quarter. Wells Fargo & Company MN now owns 17,829 shares of the biotechnology company’s stock worth $649,000 after acquiring an additional 3,472 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Uniqure by 12.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 18,747 shares of the biotechnology company’s stock worth $682,000 after acquiring an additional 2,129 shares in the last quarter. BlackRock Inc. grew its holdings in Uniqure by 3.6% during the 3rd quarter. BlackRock Inc. now owns 481,106 shares of the biotechnology company’s stock worth $17,507,000 after acquiring an additional 16,680 shares in the last quarter. Finally, Credit Suisse AG grew its holdings in Uniqure by 20.8% during the 3rd quarter. Credit Suisse AG now owns 28,271 shares of the biotechnology company’s stock worth $1,028,000 after acquiring an additional 4,859 shares in the last quarter. 60.52% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This news story was originally posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/2019/03/24/uniqure-qure-shares-down-7-3/3305878.html.
About Uniqure (NASDAQ:QURE)
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Featured Story: Why is cost of goods sold important?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.